This initiative will provide the necessary investments to
advance first-in-class drug - apabetalone for the potential
treatment of COVID-19 within the Arab-African Economy
From
left to right: Mr. Shazaad Mohammed - President of GCEI
Consultants; His Excellency Dr. Hani Abu Zaid, President of the
Supreme Council for the Arab-African Economy; Mr. Donald J.
McCaffrey President & CEO Resverlogix Corp.; Mr. Winston Chin -
President & CEO Holistic Wealth Management.
CALGARY, Alberta, Canada -- November 3, 2021 --
InvestorsHub NewsWire -- Resverlogix Corp. ("Resverlogix" or the
Company") (TSX:
RVX), a world leader in epigenetics or gene regulation, is
pleased to announce today that it has entered into a cooperation
agreement with the Supreme Council of the Arab-African Economy
which has expressed an interest in providing necessary investments
and partnerships to support the entry of Resverlogix's
first-in-class drug – apabetalone into the Arab-African
Economy.
"We are excited to be collaborating with the Supreme Council of
the Arab-African Economy under the leadership of His Excellency Dr.
Hani Abu Zaid," said Donald J. McCaffrey, President & CEO of
Resverlogix. "By entering into this cooperation agreement, it will
assist our approach in strengthening our relationships,
developments, and interests within the Arab-African Economy, while
propelling the development of apabetalone," further commented Mr.
McCaffrey.
"The Supreme Council of the Arab-African Economy is pleased to
be in collaboration with Resverlogix to provide the necessary
investment and assistance to support the emergence of apabetalone
into the Arab-African Economy. We look forward to working with Mr.
McCaffrey and his team of world-class scientists and experts in the
field of epigenetics," stated His Excellency Dr. Hani Abu Zaid,
President of the Supreme Council for the Arab-African Economy.
Resverlogix has been actively working with hospitals and the
respective ministries globally to commence COVID-19 clinical trials.
On October 12th, 2021 Resverlogix received ethics
committee approval for Western Canadian sites in a Phase
2 clinical trial for apabetalone in COVID-19 patients. On November
1st, 2021 the Canadian arm of the trial began actively
recruiting patients. Additionally, a Phase 3 COVID-19 trial in the
US is anticipated to commence in coming months based on final
protocol approval.
Phase 2 Trial Overview – Canada/Brazil
Study participants will be made up of patients hospitalized with
confirmed COVID-19 cases. Participants will either receive twice
daily doses of apabetalone for up to 4 weeks alongside standard of
care, compared to standard of care alone. The primary outcome
measure of the study will be change in the World Health
Organization (WHO) Ordinal Scale for Clinical
Improvement. A total of 100 patients are expected to be
enrolled at multiple sites in Canada and Brazil. The study is
actively recruiting in the Canadian arm. The full study protocol
can be found on clinicaltrials.gov.
About the Supreme Council of Arab-African Economy
- The Council's
Mandate
The Supreme Economic Council for the Arab-African Economy is an
economic-diplomatic body recognized by the United Nations, European
Union, Arab League, and the Common Market for Eastern and Southern
Africa (COMESA). The Supreme Economic Council for the Arab-African
Economy specializes in promoting and facilitating investments and
trade in member nations and affiliates to strengthen their
economies.
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, epigenetic small
molecule, or gene regulating, therapeutic candidate. It is a
selective BET (bromodomain
and extra-terminal)
inhibitor, which works in preventing disease by turning genes on
and/or off through regulation of gene expression. The
prevalence of BET proteins in the human body allows
apabetalone, through its unique mechanism of action, to
simultaneously target multiple disease-causing biological processes
while maintaining a well described safety profile – leading to a
new way to treat chronic disease.
Cardiology:
In February 2020, apabetalone became the first therapy of its
kind to receive Breakthrough Therapy Designation by the US Food and
Drug Administration (FDA) – for a major cardiovascular indication –
following the ground-breaking findings from the BETonMACE Phase
Three study. Data from BETonMACE showed apabetalone can potentially
prevent major adverse cardiac events among high-risk cardiovascular
disease patients who also have type 2 diabetes mellitus.
Covid-19:
On March 23, 2020, Resverlogix launched its
COVID-19 program, enlisting world-renowned collaborators. Studies
demonstrate that apabetalone has the potential to act against
COVID-19 with a unique dual-mechanism: the first pillar of
apabetalone's dual-mechanism is preventing viruses from entering
the cells and replicating; the second pillar is averting runaway
inflammatory reactions that can cause severe and lasting organ
damage. A Phase 2 clinical trial is evaluating apabetalone
in combination with standard of care for patients hospitalized with
COVID-19. Apabetalone treatment could potentially reduce the
severity and duration of COVID-19. Apabetalone's unique
dual-mechanism also means that it is likely to show efficacy
against COVID-19 variants and may even help fight other related
viruses.
Apabetalone is the only drug of its class with a
well-established safety record in human clinical trials, with well
over 4200 patient-years on drug across 10 clinical trials.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage
biotechnology company and the world leader in epigenetics, or gene
regulation, with the goal of developing first-in-class therapies
for the benefit of patients with chronic disease.
Resverlogix is commercializing a new class of epigenetic
therapies designed to regulate gene expression, turning
disease-associated genes "on" or "off". We aim to improve patients'
lives by restoring biological functions – altered by serious
illnesses such as cardiovascular disease – back to a healthier
state.
The Company's clinical program is focused on evaluating the lead
epigenetic candidate apabetalone for the treatment of
cardiovascular disease and associated comorbidities, and
COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us: Twitter: @Resverlogix_RVX.
LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
www.resverlogix.com
Forward Looking Statements:
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information related to the Company's discussions with
the Supreme Council of Arab-African Economy,
the Company's clinical trials and the potential role
of apabetalone in the treatment of patients with COVID-19 (and
potentially other viruses), cardiovascular disease and associated
comorbidities and other chronic diseases. Our actual results,
events or developments could be materially different from those
expressed or implied by these forward-looking statements. We can
give no assurance that any of the events or expectations will occur
or be realized. By their nature, forward-looking statements are
subject to numerous assumptions and risk factors including those
discussed in our Annual Information Form and most recent MD&A
which are incorporated herein by reference and are available
through SEDAR at www.sedar.com. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Resverlogix (PK) (USOTC:RVXCF)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Resverlogix (PK) (USOTC:RVXCF)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
